Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus

Area of Science:

• Pediatric Rheumatology
• Hematology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems.
• Thrombocytopenia, a condition characterized by low platelet counts, is a common hematologic manifestation in SLE.
• The relationship between thrombocytopenia, its severity, and the risk of thromboembolic events (TEs) in pediatric SLE requires further elucidation.

Purpose of the Study:

• To determine the incidence and outcome of thrombocytopenia in children diagnosed with SLE.
• To investigate the association between thrombocytopenia and other SLE manifestations, particularly TEs.
• To identify risk factors for TEs in pediatric patients with SLE.

Main Methods:

• Retrospective review of 106 pediatric patients diagnosed with SLE between 1992 and 2001.
• Analysis of patient data including incidence of thrombocytopenia, its severity and duration, and occurrence of TEs.
• Statistical assessment of the association between thrombocytopenia, lupus anticoagulant, anticardiolipin antibodies, and TEs.

Main Results:

• Thrombocytopenia was present in 50% of pediatric SLE patients, with 34% experiencing moderate or severe degrees.
• Sustained thrombocytopenia occurred in 29% of the cohort.
• Lupus anticoagulant was significantly associated with an increased risk of TEs, whereas anticardiolipin antibodies and sustained thrombocytopenia were not.

Conclusions:

• Thrombocytopenia is a frequent finding in pediatric SLE, with a notable proportion experiencing sustained low platelet counts.
• The presence of lupus anticoagulant is a key predictor of thromboembolic events in this population.
• Further research is warranted to understand the complex interplay between hematologic abnormalities and thrombotic risk in pediatric SLE.